Vyome Holdings, Inc. (HIND)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 35K | 37K | 32K | 27K |
| Gross Profit | 18K | 22K | 17K | 12K |
| Operating Income | (869K) | (1.4M) | (1.1M) | (863K) |
| Net Income | (8.6M) | (1.1M) | (963K) | (686K) |
| Diluted EPS | $-3.12 | N/A | $-0.15 | $-0.10 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 383K | 416K | 257K | 320K |
| Gross Profit | 146K | 283K | 195K | 219K |
| Operating Income | (1.1M) | (768K) | (1.0M) | (2.7M) |
| Net Income | (1.3M) | (720K) | (1.4M) | (10.3M) |
| Diluted EPS | $-0.05 | $-0.03 | $-0.26 | $-4.86 |